PET imaging using a radiolabeled antibody picked up clear cell renal cell carcinoma and could help avert unnecessary biopsies ...

ALLO-316 targets CD70, a surface antigen highly expressed in renal cell carcinoma, offering potential for heavily pretreated patients. The FDA's designation is based on early evidence from the phase 1 ...

This year alone, 81,000 people will be diagnosed with kidney cancer. Renal cell carcinoma is the most common form of it.

In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels ...

Renal cell carcinoma (RCC) is the most common tumor of the kidney, constituting 80% to 85% of primary renal ... allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is ...

This year alone, 81,000 people will be diagnosed with kidney cancer and more than 14,000 will die from it. Renal cell carcinoma is the most common form of it, and it can be difficult to treat as ...

Preliminary Phase 1 clinical data expected in the first half of 2025 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...